Dana Piovesan
About Dana Piovesan
Dana Piovesan is a scientist currently working at Arcus Biosciences in Hayward, California, where she has held various roles since 2017. She has a strong background in immunology, having worked at several prestigious institutions and contributed to significant research in cancer immunotherapy.
Work at Arcus Biosciences
Dana Piovesan has been employed at Arcus Biosciences since 2020, currently holding the position of Scientist. Prior to this role, Dana progressed through various positions within the company, including Senior Research Associate from 2019 to 2020 and Research Associate I from 2017 to 2018. Throughout these roles, Dana has contributed to significant research initiatives, including the discovery and characterization of novel hypoxia-inducible factor (HIF)-2α inhibitors and the development of AB308, an anti-TIGIT antibody aimed at enhancing immune activation.
Education and Expertise
Dana Piovesan earned a Master of Biomedical Science with a focus on Immunology from the University of Melbourne, completing the program from 2015 to 2016. Prior to this, Dana obtained a Bachelor of Science (BSc) with a major in Microbiology, Infection, and Immunology from the same institution, studying from 2011 to 2013. This educational background has provided a solid foundation in immunological research, which Dana has applied in various professional roles.
Background
Dana Piovesan's research career began with an Undergraduate Research Opportunity Program (UROP) at the Walter and Eliza Hall Institute of Medical Research in 2013. Dana continued to build experience in immunology through roles at the same institute as a Research Assistant in the Immunology Division from 2013 to 2015, and later as a Research Assistant at Monash University for seven months in 2016. Dana also served as a Teaching Demonstrator at the University of Melbourne in 2016, further enhancing expertise in the field.
Research Contributions
Dana Piovesan has made significant contributions to the field of immunology through various research projects. Notable work includes involvement in the development of Fc-silent anti-TIGIT antibodies, which enhance anti-tumor immunity. Dana has also participated in research targeting CD73 with AB680 (Quemliclustat) to restore immune functionality. Research findings have been presented at prestigious conferences such as the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC).